Liquidia Slips as Post-Earnings Selling Continues

Liquidia Corporation (LQDA) is down 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be continued post-earnings selling after last week’s quarterly report, even though the underlying operating results were strong. This could be because investors are taking profits after the stock’s huge multiyear run and reassessing valuation after a recent analyst downgrade and target-price cut.

Details:

The company’s second-quarter results showed YUTREPIA net product sales of about $170.4 million, up 31% from the prior quarter, alongside a fourth straight quarter of improving profitability.

Despite those strong numbers, the stock fell sharply after the August 12 results, suggesting the market may have already priced in much of the growth and reacted with a sell-the-news move.

A recent research note lowered its target price to $78, while another analyst downgrade around the earnings release pointed to a more cautious near-term view even as some firms kept bullish ratings.

The shares have delivered an outsized gain over the last three years, which can make a biotech name more vulnerable to profit-taking and volatility when expectations are elevated.

Sources:

Liquidia Corporation, Yahoo Finance, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LQDA Insider Trading Activity

$LQDA insiders have traded $LQDA stock on the open market 121 times in the past 6 months. Of those trades, 1 have been purchases and 120 have been sales.

Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:

STEPHEN M BLOCH has made 0 purchases and 48 sales selling 1,757,692 shares for an estimated $118,662,601.
ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 21 sales selling 486,565 shares for an estimated $24,914,862.
MICHAEL KASETA (CFO and COO) has made 0 purchases and 9 sales selling 339,388 shares for an estimated $14,243,260.
PAUL B MANNING has made 0 purchases and 5 sales selling 200,000 shares for an estimated $12,782,058.
RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 5 sales selling 98,680 shares for an estimated $7,035,793.
SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 7 sales selling 118,400 shares for an estimated $4,586,119.
KATHERINE RIELLY-GAUVIN has made 0 purchases and 2 sales selling 55,182 shares for an estimated $4,087,434.
SARAH KREPP (Chief Human Resource Officer) has made 0 purchases and 5 sales selling 37,301 shares for an estimated $2,485,739.
RAMAN SINGH sold 29,494 shares for an estimated $1,773,435
RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 3 sales selling 28,430 shares for an estimated $1,579,287.
DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 5 sales selling 17,279 shares for an estimated $1,039,054.
JASON ADAIR (Chief Business Officer) has made 0 purchases and 5 sales selling 16,540 shares for an estimated $931,303.
PARTNERS LP CALIGAN has made 1 purchase buying 5,300 shares for an estimated $317,894 and 1 sale selling 5,300 shares for an estimated $317,894.
SANJEEV KHINDRI (Chief Development Officer) has made 0 purchases and 3 sales selling 5,319 shares for an estimated $355,351.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive LQDA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$LQDA Hedge Fund Activity

We have seen 224 institutional investors add shares of $LQDA stock to their portfolio, and 128 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 5,299,442 shares (+96.5%) to their portfolio in Q2 2026, for an estimated $422,524,510
FULLER & THALER ASSET MANAGEMENT, INC. added 1,209,604 shares (+inf%) to their portfolio in Q2 2026, for an estimated $96,441,726
STATE STREET CORP added 1,148,796 shares (+61.1%) to their portfolio in Q2 2026, for an estimated $91,593,505
PRICE T ROWE ASSOCIATES INC /MD/ added 987,213 shares (+103.6%) to their portfolio in Q2 2026, for an estimated $78,710,492
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 674,033 shares (+inf%) to their portfolio in Q2 2026, for an estimated $53,740,651
JANE STREET GROUP, LLC removed 654,343 shares (-82.2%) from their portfolio in Q2 2026, for an estimated $52,170,767
AMERICAN CENTURY COMPANIES INC added 542,131 shares (+inf%) to their portfolio in Q2 2026, for an estimated $43,224,104

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LQDA Price Targets

Multiple analysts have issued price targets for $LQDA recently. We have seen 6 analysts offer price targets for $LQDA in the last 6 months, with a median target of $72.5.

Here are some recent targets:

Jason Gerberry from B of A Securities set a target price of $79.0 on 06/29/2026
Julian Harrison from BTIG set a target price of $109.0 on 06/22/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $75.0 on 06/05/2026
Benjamin Burnett from Wells Fargo set a target price of $62.0 on 05/12/2026
Serge Belanger from Needham set a target price of $70.0 on 05/11/2026
Andreas Argyrides from Oppenheimer set a target price of $19.0 on 03/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.